Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy

Platelets

Volumn 17, Issue 4, 2006, Pages 250-258

  Smith, Simon M G ^a,e   Judge, Heather M ^a   Peters, Gary ^b   Armstrong, Martin ^b   Fontana, Pierre ^c   Gaussem, Pascale ^c   Daly, Martina E ^d   Storey, Robert F ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c INSERM   (France)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Clopidogrel; Cytochrome P450 3A5; P2Y12; Polymorphism

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYTOCHROME P450 3A5; HEPARIN; HIRUDIN; PURINE P2Y12 RECEPTOR;

ARTICLE; BLEEDING; CELL INTERACTION; CONJUGATION; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG RESPONSE; ELECTIVE SURGERY; FLOW CYTOMETRY; GENE EXPRESSION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MONOCYTE; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE; THROMBOCYTE COUNT;

CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; MALE; OBSERVER VARIATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECEPTORS, PURINERGIC P2; TICLOPIDINE;

EID: 33745167304     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537100500475844     Document Type: Article

References (28)

1. Bertrand M, Rupprecht H-J, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 2000;102:624-629.
2. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348:1329-1339.
3. The clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New Eng J Med 2001;345:494-502.
4. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. New Engl J Med 2005;352:1179-1189.
5. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Barrera-Ramirez C, Sabate M, et al. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res 2005;115:101-108.
6. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Banuelos C, et al. High clopidogrel loading dose during coronary stenting: Effects on drug response and interindividual variability. Eur Heart J 2004;25:1903-1910.
7. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting. Response variability, drug resistance, and the effect of pretreatment platelet reactvity. Circulation 2003;107:2908-2913.
8. Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003;89:783-787.
9. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45:246-251.
10. Barragan P, Bouvier J-L, Roquebert P-O, Macaluso G, Commeau P, Comet B, et al. Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Cathet Cardiovasc Intervent 2003;59:295-302.
11. Kreutz RP, Gurbel PA. Subacute stent thrombosis in an elderly man with clopidogrel resistance. Clin Genet 2005;13:37-10.
12. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-3175.
13. von Beckerath N. A patient with stent thrombosis, clopidogrel-resistance and failure to metabolize clopidogrel to its active metabolite. Thromb Haemost 2005;93:789-791.
14. Savi P, Pereillo J, Uzabiaga M-F, Combalbert J, Picard C, Maffrand J-P, et al. Identification and biological acivity of the active metabolite of clopidogrel. Thromb Haemost 2000;84:891-896.
15. Savi P, Laboret C, Delesque N, Guette F, Lupker J, Herbert J-M. P2Y12, a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun 2001;283:379-383.
16. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003;31:53-59.
17. Lamba JK, Lin YS, Scheutz EG, Thummel KE. Genetic contribution to variable CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002;54:1271-1294.
18. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Scheutz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-391.
19. Mustert E, Haberl M, Burk O, Wolbold R, He Y-Q, Klein K, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001;11:773-779.
20. Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny J-L, Aiach M, et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003;108:989-995.
21. Fontana P, Gaussem P, Aiach M, Fiessinger J-N, Emmerich J, Reny J-L. P2Y12 H2 haplotype is associated with peripheral arterial disease: A case-control study. Circulation 2003;108:2971-2973.
22. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: Results from the ARMYDA-2 (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty) study. Circulation 2005;111:2099-2106.
23. Storey RF, Sanderson HM, White AE, May JA, Cameron KE, Heptinstall S. The central role of the P2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol 2000;110:925-934.
24. Taubert D, Kastrati A, Harlfinger S, Gorchakova O, Lazar A, von Beckerath N, et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 2004;92:311-316.
25. von Beckerath N, von Beckerath O, Koch W, Eichinger M, Schomig A, Kastrati A. P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Coagul Fibrinolysis 2005;16:199-204.
26. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Cavallari U, Trabetti E, et al. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thrombosis Research 2005;116:491-497.
27. Muller I, Seyfarth M, Rudiger S, Wolf B, Pogatsa-Murray G, Schomig A, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001;85:92-93.
28. Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005;45:1392-1396.